Alkaline phosphatase-to-albumin ratio as a novel predictor of long-term adverse outcomes in coronary artery disease patients who underwent PCI
Author(s) -
XinYa Dai,
YingYing Zheng,
Junnan Tang,
Wei Wang,
Qianqian Guo,
Shan-Shan Yin,
Jianchao Zhang,
MengDie Cheng,
Feng-Hua Song,
Zhiyu Liu,
Kai Wang,
Li-Zhu Jiang,
Lei Fan,
Xiao-Ting Yue,
Yan Bai,
Zeng-Lei Zhang,
Rujie Zheng,
Jinying Zhang
Publication year - 2021
Publication title -
bioscience reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.938
H-Index - 77
eISSN - 1573-4935
pISSN - 0144-8463
DOI - 10.1042/bsr20203904
Subject(s) - medicine , percutaneous coronary intervention , conventional pci , coronary artery disease , cardiology , proportional hazards model , adverse effect , surgery , myocardial infarction
Alkaline phosphatase (ALP) and albumin (ALB) have been shown to be associated with coronary artery disease (CAD), and it has been reported that alkaline phosphatase-to-albumin ratio (AAR) is associated with the liver damage and poorer prognosis of patients with digestive system malignancy. Moreover, several previous studies showed that there was a higher incidence of malignancy in CAD patients. However, to our knowledge, the relationship between AAR and long-term adverse outcomes in CAD patients after undergoing percutaneous coronary intervention (PCI) has not been investigated. Therefore, we aim to access the relation between AAR and long-term adverse outcomes in post-PCI patients with CAD.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom